During the past two decades, magnetic resonance imaging (MRI) has become a powerful technique in clinical diagnosis and biological molecular imaging. [1] [2] [3] [4] A significant advantage of MRI is the ability to acquire tomographic information of whole animals with high spatial resolution and soft tissue contrast. In addition, images are acquired without the use of ionizing radiation [e.g., X-ray and CT (computed tomography)] or radiotracers [e.g., positron emission tomography (PET) and single photon emission computed tomography (SPECT)] permitting long-term longitudinal studies. Since spatial resolution increases with magnetic field strength, the ability to track small cell populations has been realized.
MRI contrast agents are frequently utilized to permit the visual differentiation of cells and tissues that are magnetically similar but histologically distinct. Paramagnetic gadolinium-(III) complexes are the most widely used contrast agents, as Gd III reduces the longitudinal relaxation time (T 1 ) of local water protons due to its high magnetic moment and symmetric S state. Areas enriched with Gd III exhibit an increase in signal intensity and appear bright in T 1 -weighted images. Furthermore, chelation of the Gd III ion (required to decrease latent toxicity) provides a means for chemical modification with targeting or bioactive moieties and cell transduction domains.
Recent advances in design and amplification strategies have produced a wide variety of bioactivatable contrast agents for investigating biologically important events such as ion fluctuation, enzyme activity, peroxide evolution, and temperature variation. [5] [6] [7] [8] [9] [10] [11] [12] However, the majority of these agents are incapable of penetrating cells and therefore are of limited use in cell tracking experiments.
Recent results suggest that Gd III contrast agents have shown promise in cell tracking and fate-mapping experiments. For example, tracking stem cells in adult rat brains post stroke and monitoring b-islet cell transplantation has demonstrated potential. [13] [14] [15] However, there are few examples of MR probes with the essential characteristics of high Gd III loading for enhanced contrast coupled with facile cell uptake and long-term cell retention. Herein, we report a multimodal, cell permeable, Gd III enriched polyvalent DNA-gold nanoparticle conjugate (DNA-Gd III @AuNP) for cellular MR imaging. This conjugate takes advantage of high cellular uptake, excellent stability, and high Gd III loading of polyvalent DNA-AuNPs. [16, 17] These are properties not shared by all nanostructures and are a result of the dense loading of the oligonucleotides on the surface of the DNA-AuNPs and their ability to bind to proteins, which facilitates endocytosis. [18, 19] In addition to gene regulation, DNA-AuNPs have been used in detection systems for DNA, proteins, metal ions, small molecules, and intracellular siRNA. [18, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] These Gd III enriched DNA-AuNP conjugates represent a new class of MR contrast agents with the capability of highly efficient cell penetration and accumulation that provides sufficient contrast enhancement for imaging small cell populations with mm Gd III incubation concentrations. Moreover, these conjugates are labeled with a fluorescent dye permitting multimodal imaging to confirm cell uptake and intracellular accumulation, and providing a means for histological validation. [32] NP conjugates were prepared by reacting citrate-stabilized gold nanoparticles with thiol-labeled 24-mer poly-dT oligonucleotides. DNA oligomers were synthesized on a solid support with post-modification carried out in solution. The poly-dT contained five conjugation sites (hexylamino labeled dT groups conjugated with a cross linker, azidobutyrate-Nhydroxysuccinimidester) for covalently attaching Gd III complexes through click chemistry. Click chemistry has proven to be an efficient method for preparing Gd III -based MR contrast agents with high synthetic yields and increased relaxivity. [33] After purification by RP-HPLC, the DNA-Gd III conjugates were characterized by MALDI-MS, which confirmed formation of the conjugates. The DNA-Gd III conjugates were then immobilized on citrate-stabilized AuNPs following literature procedures used to make the analogous Gd III -free NPs to yield DNA-Gd III @AuNPs (Scheme 1). [34] Excess DNA-Gd III was removed by repeated centrifugation and resuspension of the NPs until the supernatant was free of Gd III . When suspended in aqueous solution, the NP conjugates appear deep red due to the plasmon resonance of the Au at 520 nm, and they are stable for months at room temperature (see Supporting Information). Cy3-labeled DNA oligomers were synthesized in order to produce Cy3-DNAGd III @AuNPs for fluorescence microscopy and flow cytometry to confirm cell uptake and labeling efficiency, respectively.
The relaxation efficiency of these newly synthesized MR contrast agent conjugates were determined by taking the slope of a plot of the measured 1/T 1 Table 1 ). This doubling in relaxivity is consistent with Soloman-Bloomberg-Morgan theory where decreases in rotational correlation time, t r , result in increases in r 1 . [1, 19] It is important to note that the relaxivity of Gd III increases further when DNA-Gd III is immobilized on the surface of AuNPs through gold-thiol linkages. We have examined two different sizes of AuNPs (13 and ) at 60 MHz and 25 8C. The higher relaxivity of this conjugate is a result of two water molecules (as opposed to one) coordinated to each Gd III ion, and the increased rigidity due to the nature of the attachment of the chelates to the particle surface. [36] T (Figures 1 and  2) . At all concentrations the Gd III uptake was more than 50-fold higher for DNA-Gd III @AuNPs compared to DOTAScheme 1. Synthesis of Cy3-DNA-Gd III @AuNP conjugates. [37] Previous reports have suggested that at least 10 7 -10 9 Gd III ions per cell are necessary to produce detectable contrast enhancement. [38] These reports, however, used mm incubation concentrations of Gd III to reach that detection threshold due to the limited cellular uptake (lower transduction efficiency) and low relaxivity of the clinical agents used. Furthermore, compared with previous cell-permeable contrast agents using either the small transduction molecule stilbene and oligomeric polyarginine-conjugated DOTA-Gd III , the DNA-Gd III @AuNP system exhibits the highest cellular uptake.
[ 39] To demonstrate that mm Gd III incubation concentrations of DNA-Gd III @AuNP conjugates were sufficient to produce significant T 1 -weighted contrast enhancement of small cell populations, cells were labeled and imaged at 14.1 T. Specifically, NIH/3T3 cells were incubated with 5.0 mm or 20 mm (Gd III concentration) of DOTA-Gd III or DNA-Gd III @AuNP for 24 h. T 1 -weighted MR images of cell pellets were acquired in 1.0 mm diameter glass capillaries, each containing approximately 10 6 cells (Figure 3) . T 1 analysis revealed a 43 % and 29 % T 1 reduction with 20 mm and 5.0 mm DNA-Gd III @AuNP labeled cell pellets, respectively. Cell pellets incubated with DOTA-Gd III at either concentration showed no significant difference from control cell pellets. To our knowledge, these results represent the lowest reported incubation concentration of a Gd III complex or conjugate to produce a greater than 40 % reduction of T 1 in cell pellets (see Supporting Information). [40] For comparison, MRI has been applied to tracking Gd III labeled b-islets for transplantation and stem cell migration with DO3AHP-Gd III with incubation concentrations ranging from 20-50 mm. [41] We are reporting a 1000-fold decrease in Gd III incubation concentration to obtain essentially the same contrast enhancement. We have found that efficient delivery and accumulation of Gd III complexes is critical for improving the detection limit for high resolution cellular imaging at high magnetic field.
The DNA-Gd III @AuNP conjugates are resistant to nuclease degradation which is important for long term cell tracking.
[14] We have determined (by ICP-MS) that the ratio of Au to Gd III , after cell internalization, remains constant for at least 24 h. This implies that the DNA-Gd III @AuNP assembly did not undergo enzyme digestion over this time period which is consistent with previously published results using similar DNA-AuNP conjugates. [42] To confirm the intracellular accumulation and uptake efficiency of the DNA-Gd III @AuNPs, bimodal AuNP conjugates were synthesized by conjugating Cy3 to the 5' end of the DNA-Gd III strands. The ratio of optical to MR signal can be adjusted by altering the stoichiometry of the Cy3-labeled DNA-Gd III strands with non-labeled strands. Specifically, NIH/3T3 and HeLa cells were labeled with 0.1-0.2 nm Cy3-DNA-Gd III @AuNPs for 24 h, rinsed three times with DPBS, and imaged using a confocal laser scanning microscope (CLSM).
The fluorescence micrographs show that the Cy3-DNAGd III @AuNPs localize in small vesicles in the perinucleur region, which is consistent with previous reports that show AuNP conjugates are taken up through an endocytic mechanism (Figure 4) . [43] A second batch of cells was incubated under the same conditions and allowed to leach for 24 h (media with contrast agent is replaced with fresh media after Cell labeling efficiency was evaluated using analytical flow cytometry and showed that at 0.3 nm Cy3-DNAGd III @AuNP incubation concentration, 80 % of the cells were labeled after 4.0 h. In both NIH/3T3 and HeLa cells, labeling reached 100 % after a 24 h incubation (see Supporting Information). Importantly, we did not observe any evidence of cell toxicity or cell number variation under any of the conditions tested using DNA-Gd III @AuNPs or DOTAGd III (see Supporting Information).
In conclusion, we have demonstrated a new multimodal, cell permeable MR contrast agent based upon polyvalent DNA-AuNPs. These particles exhibit excellent biocompatibility and stability, high Gd III loading, a greater than 50-fold increase in cell uptake compared to the clinically available contrast agent DOTA-Gd III , and relatively high relaxivity. Work is underway to investigate the utility of these agents for in vivo applications regarding cell tracking in animal models. A primary goal of these studies will be to determine the minimum number of cells that can be detected by this approach.
When modified with a fluorophore, the DNAGd III @AuNPs can be used as multimodal imaging agents where fluorescence microscopy showed that the particles localize in the perinuclear region inside cells. Since AuNPs serve as CT contrast agents, these DNA-Gd III @AuNP conjugates have promise as multimodal imaging probes for MR, fluorescence, and CT. The library of available probes for cancer and biological cellular imaging is growing and the strategy presented in this work represents a promising new addition. [20, [44] [45] [46] [47] 
